Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M.
Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
Tangri N, Rastogi A, Nekeman-Nan C, Hong LS, Ozaki A, Franzén S, Sofue T.
Adv Ther. 2024 Mar;41(3):1151-1167. doi: 10.1007/s12325-023-02773-x. Epub 2024 Jan 19.
PMID:38240949
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, Yarden A, Khazim K, Shehadeh N, Melzer Cohen C.
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
Batista JL, Hariri A, Maski M, Richards S, Gudivada B, Raynor LA, Ponce E, Wanner C, Desnick RJ.
Clin Kidney J. 2024 Jul 2;17(8):sfae194. doi: 10.1093/ckj/sfae194. eCollection 2024 Aug.
PMID:39139182
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.
J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.
PMID:30314978
The slope of the initial temperature drop predicts acute pulmonary vein isolation using the second-generation cryoballoon.
Deubner N, Greiss H, Akkaya E, Zaltsberg S, Hain A, Berkowitsch A, Güttler N, Kuniss M, Neumann T.